Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Rosuvastatin Efficacy in Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients After Chemotherapy

NCT07254221 is registered in ClinicalTrials.gov with Shiraz University of Medical Sciences as lead sponsor.

NCT NCT07254221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07254221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Rosuvastatin Efficacy in Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients After Chemotherapy
Lead sponsor
Shiraz University of Medical Sciences
Phase
Phase 4
Overall status
Not yet recruiting
Start date
February 1, 2026
Completion date
April 21, 2028
Enrollment
400 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

anthracycline related cardiotoxicity in breast cancer, anthracycline-induced cardiac toxicity, anthracycline-induced cardiotoxicity, breast cancer